



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2015 Certified Company

CIN No. : L24239MH1988PLC047759

SYNCOM/SE/2023-24

14th August, 2023

Online filing at: www.listing.bseindia.com and
<https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp>

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015- Submission of the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2023.

Dear Sir/Ma'am,

This is in continuation of our letter no. SYNCOM/SE/2023-24 dated 3rd August 2023 regarding intimation of Board meeting for consideration and approval of Quarterly Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2023.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter ended 30th June, 2023, in PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on Monday, 14th August, 2023.

The Board Meeting commenced at 11:00 A.M. and concluded at 2:15 P.M.

The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company.

You are requested to take on record the above said Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report for your reference and record.

Thanking You
Yours Faithfully

For, SYNCOM FORMULATIONS (INDIA) LIMITED

CS VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER



Encl: Unaudited Standalone and Consolidated Financial Results and Limited Review Report.

Bringing a smile on every face...

Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Third Month ended 30th June, 2023 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)


We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company")**, for the period ended June, 30, 2023 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C



CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 23079452BGQYAM8550



Place: Indore
Date: 14th August, 2023



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off. - 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works - 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

(Rs. In Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Year Ended
		30-06-2023	31-03-2023	30-06-2022	31-03-2023
		Unaudited	Audited*	Unaudited	Audited
1	Revenue from Operations	5936.43	6136.92	5140.04	22464.39
2	Other Income	187.74	677.94	297.97	1460.95
3	Total Income (1 + 2)	6124.17	6814.86	5438.01	23925.34
4	EXPENSES				
	(a) Cost of materials consumed	2265.31	2554.84	2303.28	9946.06
	(b) Purchases of Stock-in-Trade	914.08	1321.16	867.06	4261.14
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	390.53	(96.49)	152.08	5.03
	(d) Employee benefits expense	762.81	719.77	497.86	2586.56
	(e) Finance costs	112.17	129.19	50.37	313.02
	(f) Depreciation and amortization expense	110.00	116.78	99.50	453.93
	(g) Other expenses	987.93	1043.86	971.10	3704.28
	Total expenses (4)	5542.83	5789.11	4941.25	21270.02
5	Profit/(loss) before exceptional items and tax (3- 4)	581.34	1025.75	496.76	2655.32
6	Exceptional Items	0.00	1.33	0.00	1.33
7	Profit/(loss) before tax (5 - 6)	581.34	1027.08	496.76	2656.65
8	Tax expense:				
	(1) Current tax	160.30	258.84	103.00	664.84
	(2) Deferred tax	(3.81)	(78.41)	7.00	(15.26)
9	Profit (Loss) for the period from continuing operations (7-8)	424.85	846.65	386.76	2007.07
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	424.85	846.65	386.76	2007.07
14	Other Comprehensive Income				
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	206.77	48.85	(85.36)	196.36
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	631.62	895.50	301.40	2203.43
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves				16201.47
18	Earnings per equity share (for continuing operation):				
	(1) Basic	0.07	0.10	0.03	0.24
	(2) Diluted	0.07	0.10	0.03	0.24
19	Earnings per equity share (for discontinued operation):				
	(1) Basic	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)				
	(1) Basic	0.07	0.10	0.03	0.24
	(2) Diluted	0.07	0.10	0.03	0.24

Place: Indore

Date: 14/08/2023

For, Syncom Formulations (India) Limited



Kedarnal Shankarlal Bankda
Chairman & Wholetime Director

DIN: 00023050



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works :- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY UNAUDITED RESULTS

S. No.	Particulars	Quarter Ended			Rs. In Lacs
		30-06-2023		30-06-2022	Year Ended
		Unaudited	Audited*	Unaudited	31-03-2023
1	Segment Revenue				
	a) Pharmaceuticals Drugs & Formulations	5559.41	5932.04	4845.80	21037.66
	b) Trading of Commodities	456.98	803.01	510.41	2552.40
	c) Renting of Property	107.78	79.81	81.80	335.28
	Total Segment Revenue	6124.17	6814.86	5438.01	23925.34
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00
	Revenue from Operations	6124.17	6814.86	5438.01	23925.34
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment				
	a) Pharmaceuticals Drugs & Formulations	595.98	1081.39	447.63	2620.14
	b) Trading of Commodities	-5.70	13.25	17.70	32.43
	c) Renting of Property	103.23	61.63	81.80	317.10
	Total Profit before tax	693.51	1156.27	547.13	2969.67
	Less: i) Interest	112.17	129.19	50.37	313.02
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00
	Profit before tax	581.34	1027.08	496.76	2656.65
3	(Segment Asset-Segment Liabilities)				
	Segment Asset				
	a) Pharmaceuticals Drugs & Formulations	32038.86	32002.05	31308.92	32002.05
	b) Trading of Commodities	980.14	958.89	472.73	958.89
	c) Renting of Property	4733.45	0.00	4749.89	4733.45
	Total Segment Asset	37752.45	32960.94	36531.53	37694.39
	Un-allocable Assets	0.00		0.00	
	Net Segment Asset	37752.45	32960.94	36531.53	37694.39
	Segment Liabilities				
	a) Pharmaceuticals Drugs & Formulations	11095.28	11749.56	12168.52	11749.56
	b) Trading of Commodities	260.49	179.91	221.75	179.91
	c) Renting of Property	163.56	163.44	158.81	163.44
	Total Segment Liabilities	11519.33	12092.91	12549.08	12092.91
	Un-allocable Liabilities	0.00	0.00	0.00	0.00
	Net Segment Liabilities	11519.33	12092.91	12549.08	12092.91

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14/08/2023.
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June, 2023. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs. 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. Out of which the company has already utilized the amount of Rs. 3446.33 Lakhs (Including capital work in progress), Remaining unutilized amount of Rs. 585.17 Lakhs will be used in the subsequent period. Trial Production has been started from 30th June 23 and Commercial Production will be Started by end of Aug 23. There is no deviation in the project till 30th June, 2023 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately
- The Company has incorporated 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd. and Sante Biotech Pvt. Ltd. on 21st July, 2022 and Vincit Biotech International Pvt. Ltd. on 25th July, 2022. The Subsidiary Companies have obtained Drug Licenses and other approvals from the Competent Authorities. , during the Quarter under review, these Subsidiary Companies have started Business Activities

Place: Indore

Date: 14/08/2023

For, Syncom Formulations (India) Limited

[Signature]

Kedarmal Shankarlal Bankda
Chairman & Wholtime Director
DIN: 00023050

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Three Months ended 30th June, 2023 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,

The Board of Directors

SYNCOM FORMULATIONS (INDIA) LIMITED

Indore (M.P.)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended June 30, 2023 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
2. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entity:

S. No.	Name of the Company	Relationship with the Holding Company
1.	Santa Biotech Pvt. Ltd.	Wholly Owned Subsidiary
2.	Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
3.	Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary



5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 14th August 2023

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C

CA Manish Mittal
(Partner)

M. No. 079452

UDIN: 23079452BGQYAN3397





SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7, Niraj Industrial Estate Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website - www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023


(Rs. In Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Year Ended
		30-06-2023	31-03-2023	30-06-2022	31-03-2023
		Unaudited	Audited*	Unaudited	Audited
1	Revenue from Operations	5983.58	6097.95	5140.04	22425.42
2	Other Income	187.47	676.98	297.97	1459.99
3	Total Income (1 + 2)	6171.05	6774.93	5438.01	23885.41
4	EXPENSES				
	(a) Cost of materials consumed	2265.31	2554.84	2303.28	9946.06
	(b) Purchases of Stock-in-Trade	921.42	1321.16	867.06	4261.14
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	368.22	(139.13)	152.08	(37.61)
	(d) Employee benefits expense	762.81	719.77	497.86	2586.56
	(e) Finance costs	112.17	129.27	50.37	313.10
	(f) Depreciation and amortization expense	110.00	116.78	99.50	453.93
	(g) Other expenses	1019.85	1045.17	971.10	3706.30
	Total expenses (4)	5559.78	5747.86	4941.25	21229.48
5	Profit/(loss) before exceptional items and tax (3- 4)	611.27	1027.07	496.76	2655.93
6	Exceptional Items	0.00	1.33	0.00	1.33
7	Profit/(loss) before tax (5 - 6)	611.27	1028.40	496.76	2657.26
8	Tax expense:				
	(1) Current tax	175.45	259.45	103.00	665.45
	(2) Deferred tax	(3.81)	(78.41)	7.00	(15.26)
9	Profit (Loss) for the period from continuing operations (7-8)	439.63	847.36	386.76	2007.07
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	439.63	847.36	386.76	2007.07
14	Other Comprehensive Income				
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	206.77	48.85	(85.36)	196.36
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	646.40	896.21	301.40	2203.43
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	-	-	-	16201.47
18	Earnings per equity share (for continuing operation):				
	(1) Basic	0.07	0.10	0.03	0.24
	(2) Diluted	0.07	0.10	0.03	0.24
19	Earnings per equity share (for discontinued operation):				
	(1) Basic	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)				
	(1) Basic	0.07	0.10	0.03	0.24
	(2) Diluted	0.07	0.10	0.03	0.24

Place: Indore

Date: 14/08/2023

For, Syncom Formulations (India) Limited



Kedarnal Shankarlal Bankda
Chairman & Wholetime Director

DIN: 00023050

**SYNCOM FORMULATIONS (INDIA) LIMITED**

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY UNAUDITED RESULTS

S. No.	Particulars	Rs. In Lacs			
		Quarter Ended			Year Ended
		30-06-2023	31-03-2023	30-06-2022	31-03-2023
		Unaudited	Audited*	Unaudited	Audited
1	Segment Revenue				
	a) Pharmaceuticals Drugs & Formulations	5606.59	5892.11	4845.80	20997.73
	b) Trading of Commodities	456.98	803.01	510.41	2552.40
	c) Renting of Property	107.48	79.81	81.80	335.28
	Total Segment Revenue	6171.05	6774.93	5438.01	23885.41
	Less: Inter Segment Revenue	0.00	0.00	0.00	
	Revenue from Operations	6171.05	6774.93	5438.01	23885.41
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment				
	a) Pharmaceuticals Drugs & Formulations	626.21	1082.79	447.63	2620.83
	b) Trading of Commodities	-5.70	13.25	17.70	32.43
	c) Renting of Property	102.93	61.63	81.80	317.10
	Total Profit before tax	723.44	1157.67	547.13	2970.36
	Less: i) Interest	112.17	129.27	50.37	313.10
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00
	Profit before tax	611.27	1028.40	496.76	2657.26
3	(Segment Asset-Segment Liabilities)				
	Segment Asset				
	a) Pharmaceuticals Drugs & Formulations	32085.85	32090.72	31308.92	32090.72
	b) Trading of Commodities	980.14	958.89	472.73	958.89
	c) Renting of Property	4733.45	0.00	4749.89	4733.45
	Total Segment Asset	37799.44	33049.61	36531.53	37783.06
	Un-allocable Assets	0.00		0.00	
	Net Segment Asset	37799.44	33049.61	36531.53	37783.06
	Segment Liabilities				
	a) Pharmaceuticals Drugs & Formulations	11127.46	11838.21	12168.52	11838.21
	b) Trading of Commodities	260.49	179.91	221.75	179.91
	c) Renting of Property	163.56	163.44	158.81	163.44
	Total Segment Liabilities	11551.51	12181.56	12549.08	12181.56
	Un-allocable Liabilities	0.00	0.00	0.00	
	Net Segment Liabilities	11551.51	12181.56	12549.08	12181.56

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14/08/2023.
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June, 2023. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs. 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. Out of which the company has already utilized the amount of Rs. 3446.33 Lakhs (Including capital work in progress), Remaining unutilized amount of Rs. 585.17 Lakhs will be used in the subsequent period. Trial Production has been started from 30th June 23 and commercial Production will be started by end of Aug. 23 There is no deviation in the project till 30th June 2023 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately
- The Company has incorporated 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd. and Sante Biotech Pvt. Ltd. on 21st July, 2022 and Vincit Biotech International Pvt. Ltd. on 25th July, 2022. The Subsidiary Companies have obtained Drug Licenses and other approvals from the Competent Authorities. , during the Quarter under review, these Subsidiary Companies have started Business Activities
- The Company is not having any Subsidiaries as on 30th June, 2022 The Company has provided Statandalone figures for 30th June, 2022 For Comparing the same with 30th June, 2023 on Consolidated basis.

Place: Indore

Date: 14/08/2023

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda
Chairman & Wholetime Director

DIN: 00023050